| Literature DB >> 33657918 |
Dieneke Schonenberg-Meinema1, Sandy C Bergkamp1, Amara Nassar-Sheikh Rashid1, Leontien B van der Aa2, Godelieve J de Bree3, Rebecca Ten Cate2, Maurizio Cutolo4, A Elisabeth Hak5, Petra Ce Hissink Muller2, Marieke van Onna5, Taco W Kuijpers1, Vanessa Smith6,7,8, J Merlijn van den Berg1.
Abstract
OBJECTIVES: For selection of high-risk systemic lupus erythematosus (SLE) patients it is necessary to obtain indicators of disease severity that predict disease damage. As in systemic sclerosis, nailfold capillary abnormalities could be such a biomarker in SLE. The primary objective of this cross-sectional study is to describe capillary abnormalities in childhood-onset SLE (cSLE) cohort (onset < 18 years) and compare them with matched healthy controls. The secondary objective is to correlate the observed capillary abnormalities with demographical variables in both cohorts and with disease-specific variables in cSLE patients.Entities:
Keywords: Capillaroscopy; case-control; childhoodonset; pediatric; systemic lupus erythematosus
Year: 2021 PMID: 33657918 PMCID: PMC8020305 DOI: 10.1177/0961203321998750
Source DB: PubMed Journal: Lupus ISSN: 0961-2033 Impact factor: 2.911
Demographical variables and clinical characteristics of study groups.
| cSLE-patients, n = 41 | Healthy controls, n = 41 | p-Value | |
|---|---|---|---|
| Female, n (%) | 36 (87.8) | 29 (70.7) |
|
| Ethnicity, n (%) | 0.317 | ||
| African/Afro-Caribbean | 18 (43.9) | 15 (36.6) | |
| White | 15 (36.6) | 14 (36.6) | |
| North-African/Middle-Eastern | 3 (7.3) | 4 (9.8) | |
| Asian | 3 (7.3) | 5 (12.2) | |
| Mixed/other | 2 (4.9) | 2 (4.9) | |
| Age at capillaroscopy in years, median (IQR) | 17 (14–18) | 12 (11–16.5) |
|
| Raynaud’s phenomenon / acro-cyanotic symptoms, n (%) | 14 (34.1) | 2 (4.9) |
|
| Age at onset in years, median (IQR 25-75) | 14 (12.5–16) | ||
| Disease duration in months, median (IQR) | 12.9 (0.1–44.5) | ||
| Prednisone naive, n (%) | 23 (56.1) | ||
| ANA at diagnosis, n (%) | 41 (100) | ||
| ANA + anti-ds-DNA | 26 (63.4) | ||
| ANA + anti-RNP | 16 (39) | ||
| ANA + anti-Sm | 14 (34.1) | ||
| Cutaneous involvement, n (%) | 27 (65.9) | ||
| Nephritis, n (%) | 13 (31.7) | ||
| Neuropsychiatric involvement, n (%) | 6 (14.6) | ||
| Antiphospholipid antibodies, n (%) | 5 (12.2) | ||
| SLEDAI score at diagnosis, median (IQR) | 12 (8–16) | ||
| SLEDAI score at capillaroscopy, median (IQR) | 5 (3–10.5) |
Bold indicates statistically significant p values (<0.05).
aMcNemar test bWilcoxon signed rank test: ordinal variables (3 groups: white/mixed/other, Asian/North-African/Middle-Eastern and African/Afro-Caribbean) cpaired t-test.
ANA: Anti-Nuclear Antibodies; anti-ds-DNA: anti-double stranded DNA antibodies; anti-RNP: anti-Ribonucleoprotein; anti-Sm: anti-Smith antibodies; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; IQR: interquartile range.
Capillary characteristics.
| Quantitative parameters | cSLE-patients, n = 41 | Healthy controls, n = 41 | p-Value |
|---|---|---|---|
| Density per mm, mean (SD) | 6.83 (1.06) | 6.53 (0.86) | 0.117 |
| Max apical diameter in µm, median (IQR) | 37.7 (35.2–45.9) | 38.6 (32.8–41.2) | 0.206 |
| Giant capillaries per mm, mean (SD) | 0.04 (0.13) | 0.003 (0.013) |
|
| Abnormal shapes per mm, median (IQR) | 0.31 (0.13–0.73) | 0.21 (0.06–0.38) |
|
| Hemorrhages per mm, median (IQR) | 1.1 (0.39–2.34) | 0 (0–0.16) |
|
| Large pathological hemorrhages per mm | 0.07 (0–0.24) | 0 (0–0) |
|
| Pericapillary extravasations per mm | 1.11 (0.28–2.15) | 0 (0–0.13) |
|
|
| |||
| Normal capillary pattern, n (%) | 6 (14.6) | 37 (90.2) |
|
| Microangiopathy, n (%) | 28 (68.3) | 4 (9.8) | |
| Scleroderma pattern, n (%) | 7 (17.1) | 0 (0) |
Bold indicates statistically significant p values (<0.05).
Mm: millimeter; SD: standard deviation; µm: micrometer.
apaired t-test bWilcoxon signed rank test.
cnailfold capillary abnormalities which are also described in adult-onset SLE (4).
Correlations between clinical and demographical variables and amount of “large hemorrhages per mm”.
| Variable | Regression coefficient β (95% CI) cSLE-patients | p-Value | Regression coefficient β (95% CI) healthy controls | p-Value |
|---|---|---|---|---|
| Skin pigmentation (ordinal) | 0.103 (–0.001 – 0.207) | 0.052 | 0.000 (–0.051 – 0.052) | 0.990 |
| Trauma | –0.068 (–0.376 – 0.239) | 0.656 | 0.163 (0.054 – 0.271) |
|
| Raynaud/acrocyanosis | –0.087 (–0.298 – 0.124) | 0.410 | –0.037 (–0.247 – 0.174) | 0.726 |
| Treatment-naivety | –0.061 (–0.264 – 0.141) | 0.543 | ||
| Disease duration | –0.002 (–0.006 – 0.001) | 0.241 | ||
| SLEDAI at diagnosis | 0.019 (0.005 – 0.032) |
| ||
| SLEDAI at capillaroscopy | 0.021 (0.008 – 0.035) |
| ||
| Anti-RNP | –0.017 (–0.224 – 0.189) | 0.866 | ||
| Cutaneous involvement | –0.128 (–0.337 – 0.081) | 0.222 | ||
| Neuropsychiatric involvement | 0.121 (–0.162 – 0.404) | 0.392 | ||
| Nephritis | 0.260 (0.06 – 0.460) |
| ||
| Antiphospholipid antibodies | 0.000 (–0.071 – 0.072) | 0.989 |
Bold indicates statistically significant p values (<0.05).
Correlations between clinical and demographical variables and amount of “pericapillary extravasations per mm”.
| Variable | Regression coefficient β (95% CI) cSLE-patients | p-Value | Regression coefficient β (95% CI) healthy controls | p-Value |
|---|---|---|---|---|
| Skin pigmentation (ordinal) | 0.846 (0.536 – 1.157) |
| 0.146 (0.063 – 0.230) |
|
| Trauma | –0.587 (–1.740 – 0.567) | 0.310 | –0.028 (–0.253 – 0.197) | 0.803 |
| Raynaud/acrocyanosis | 0.193 (–0.612 – 0.997) | 0.631 | –0.129 (–0.521 – 0.262) | 0.507 |
| Treatment-naivety | 0.265 (–0.501 – 1.031) | 0.489 | ||
| Disease duration | 0.011 (–0.002 – 0.024) | 0.109 | ||
| SLEDAI at diagnosis | 0.034 (–0.021 – 0.090) | 0.216 | ||
| SLEDAI at capillaroscopy | 0.025 (–0.31 – 0.081) | 0.372 | ||
| Anti-RNP | 0.518 (–0.249 – 1.284) | 0.180 | ||
| Cutaneous involvement | –0.423 (–1.218 – 0.373) | 0.289 | ||
| Neuropsychiatric involvement | –0.855 (–1.901 – 0.192) | 0.106 | ||
| Nephritis | 0.564 (–0.237 – 1.366) | 0.163 | ||
| Antiphospholipid antibodies | –0.011 (–0.283 – 0.261) | 0.934 |
Bold indicates statistically significant p values (<0.05).